August 29, 2018

Media

Media & events

News

Lyndra Therapeutics Announces Notice of Allowance on Patent Covering Long-acting Pill

December 10, 2018
Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property (IP) related to Lyndra’s ultra-long-acting oral...
Read More

Lyndra Therapeutics Reports Positive Results from Pharmacokinetics (PK) Study of its Ultra-long-acting Oral Dosage Form

November 15, 2018
Study shows viability of taking once-weekly pill. Lyndra Therapeutics, which aims to make daily pills a thing of the past,...
Read More

Lyndra Announces Publication of Feasibility Study of Oral Once-Weekly Drug Delivery System for HIV Antiretroviral Therapy in Nature Communications

January 8, 2018
--Study results show novel drug delivery system achieves long-lasting levels of three highly-potent antiretrovirals in the circulation in an animal...
Read More

publications

  • Oral, Ultra–Long-Lasting Drug Delivery: Application Toward Malaria Elimination Goals
    Oral, Ultra–Long-Lasting Drug Delivery: Application Toward Malaria Elimination Goals
  • Lyndra White Paper on Adherence to Medication
    Lyndra White Paper on Adherence to Medication
stm
stm
Oral, Ultra–Long-Lasting Drug Delivery: Application Toward Malaria Elimination Goals
RESEARCH ARTICLE DRUG DELIVERY

Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals

Vol. 8, Issue 365, pp. 365ra157
DOI: 10.1126/scitranslmed.aag2374
URL : View Project
Asset 2 (3)
Asset 2 (3)
Lyndra White Paper on Adherence to Medication

Lyndra White Paper on Adherence to Medication
2016-09-24

URL : View Project

Press Coverage